Continuous lenalidomide treatment for newly diagnosed multiple myeloma

Antonio Palumbo, Roman Hajek, Michel Delforge, Martin Kropff, Maria Teresa Petrucci, John Catalano, Heinz Gisslinger, Wiesław Wiktor-Jędrzejczak, Mamia Zodelava, Katja Weisel, Nicola Cascavilla, Genadi Iosava, Michele Cavo, Janusz Kloczko, Joan Bladé, Meral Beksac, Ivan Spicka, Torben Plesner, Joergen Radke, Christian LangerDina Ben Yehuda, Alessandro Corso, Lindsay Herbein, Zhinuan Yu, Jay Mei, Christian Jacques, Meletios A Dimopoulos, MM-015 Investigators

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma.
OriginalsprogEngelsk
TidsskriftThe New England Journal of Medicine
Vol/bind366
Udgave nummer19
Sider (fra-til)1759-69
ISSN0028-4793
DOI
StatusUdgivet - 2012

Fingeraftryk Dyk ned i forskningsemnerne om 'Continuous lenalidomide treatment for newly diagnosed multiple myeloma'. Sammen danner de et unikt fingeraftryk.

Citationsformater